Renaissance Technologies
HEPA

Renaissance Technologies’s Hepion Pharmaceuticals HEPA Stock Holding History

Renaissance Technologies’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-347
Closed -$8.16K – 3608
2024
Q4 		$8.16K Buy
347
+16
+5% +$499 ﹤0.01% 3526
2024
Q3 		$11.1K Buy
+331
New +$13.1K ﹤0.01% 3455
2023
Q3 		– Sell
-267
Closed -$140K – 3838
2023
Q2 		$140K Sell
267
-17
-6% -$10.4K ﹤0.01% 3391
2023
Q1 		$221K Buy
284
+38
+15% +$28.1K ﹤0.01% 3236
2022
Q4 		$74K Buy
246
+14
+6% +$5.92K ﹤0.01% 3702
2022
Q3 		$117K Sell
232
-3
-1% -$1.83K ﹤0.01% 3541
2022
Q2 		$134K Buy
235
+108
+85% +$89.9K ﹤0.01% 3767
2022
Q1 		$163K Buy
127
+77
+154% +$85.1K ﹤0.01% 3697
2021
Q4 		$57K Buy
+50
New +$68.5K ﹤0.01% 3769
2021
Q2 		– Sell
-158
Closed -$290K – 3592
2021
Q1 		$290K Sell
158
-171
-52% -$375K ﹤0.01% 3063
2020
Q4 		$721K Buy
+329
New +$853K ﹤0.01% 2664
2020
Q1 		– Sell
-43
Closed -$231K – 3578
2019
Q4 		$231K Buy
+43
New +$166K ﹤0.01% 3156
2019
Q3 		– Sell
-10
Closed -$43K – 3532
2019
Q2 		$43K Buy
+10
New +$102K ﹤0.01% 3465

Other funds holding HEPA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies's HEPA Position: Q1 2025 in Review

Renaissance Technologies sold out of Hepion Pharmaceuticals (HEPA) in Q1 2025, closing a stake of 347 shares — an estimated $8.16K sold.

Renaissance Technologies first reported a position in HEPA in Q2 2019 and held it in 13 quarters. The position peaked at $721K in Q4 2020. 16 funds tracked by Wall St. Rank hold HEPA as of Q1 2025.

  • Renaissance Technologies reported no remaining Hepion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 347 Hepion Pharmaceuticals shares in Q1 2025, an estimated $8.16K.
  • Renaissance Technologies first reported a position in Hepion Pharmaceuticals in Q2 2019 and held it in 13 quarters.
  • Renaissance Technologies's Hepion Pharmaceuticals position peaked at $721K in Q4 2020.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.